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Abstract
Background: Defects in the glycosylphosphatidylinositol (GPI) biosynthesis pathway can result in a group of
congenital disorders of glycosylation known as the inherited GPI deficiencies (IGDs). To date, defects in 22 of the 29
genes in the GPI biosynthesis pathway have been identified in IGDs. The early phase of the biosynthetic pathway
assembles the GPI anchor (Synthesis stage) and the late phase transfers the GPI anchor to a nascent peptide in the
endoplasmic reticulum (ER) (Transamidase stage), stabilizes the anchor in the ER membrane using fatty acid
remodeling and then traffics the GPI-anchored protein to the cell surface (Remodeling stage).
Results: We addressed the hypothesis that disease-associated variants in either the Synthesis stage or
Transamidase+Remodeling-stage GPI pathway genes have distinct phenotypic spectra. We reviewed clinical data
from 58 publications describing 152 individual patients and encoded the phenotypic information using the Human
Phenotype Ontology (HPO). We showed statistically significant differences between the Synthesis and
Transamidase+Remodeling Groups in the frequencies of phenotypes in the musculoskeletal system, cleft palate,
nose phenotypes, and cognitive disability. Finally, we hypothesized that phenotypic defects in the IGDs are likely to
be at least partially related to defective GPI anchoring of their target proteins. Twenty-two of one hundred forty-
two proteins that receive a GPI anchor are associated with one or more Mendelian diseases and 12 show some
phenotypic overlap with the IGDs, represented by 34 HPO terms. Interestingly, GPC3 and GPC6, members of the
glypican family of heparan sulfate proteoglycans bound to the plasma membrane through a covalent GPI linkage,
are associated with 25 of these phenotypic abnormalities.
Conclusions: IGDs associated with Synthesis and Transamidase+Remodeling stages of the GPI biosynthesis
pathway have significantly different phenotypic spectra. GPC2 and GPC6 genes may represent a GPI target of
general disruption to the GPI biosynthesis pathway that contributes to the phenotypes of some IGDs.
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Introduction
Glycosylphosphatidylinositols (GPIs) are glycolipids that
act as membrane anchors of many cell surface proteins.
The GPI-anchor biosynthesis pathway covalently at-
taches the glycolipid to the C-termini of nascent pro-
teins as a post-translational modification [1]. Defects in
this pathway represent a relatively new subclass of con-
genital disorders of glycosylation (CDG) termed inher-
ited GPI deficiencies (IGDs), which are the result of
mutations in one of nearly 30 genes that encode por-
tions of the GPI biosynthetic pathway [2].
The GPI-anchor biosynthesis can be broken down into
a Synthesis and a Transamidase+Remodeling stage
(Fig. 1). The first or Synthesis stage results in the step-
wise construction of the GPI anchor. The second or
Transamidase+Remodeling-stage involves the transfer of
a nascent peptide to the GPI anchor by the transamidase
complex and results in fatty acid remodeling necessary
to stabilize the anchor in the membrane. This happens
possibly in conjunction with lipid raft formation before
it is trafficked by secretory vesicles to the cell surface [7,
8]. Approximately 150 proteins are GPI anchored, in-
cluding enzymes, structural molecules, receptors, and
regulatory proteins [1]. Misregulation of the GPI-
anchored proteins (GPI-AP), which occurs as a result of
mutations in the GPI-biosynthesis pathway, leads to the
variety of phenotypes observed in IGD.
IGD disorders are more common than initially rec-
ognized. A study of 4293 parent-child developmental
disability trios suggested that IGDs alone account for
0.15% of all developmental disorders [9]. The IGD-
associated disorders listed in Table 1 result from
complete or partial inactivation of these GPI biosyn-
thesis enzymes. The phenotypes that characterize
these disorders often include seizures, intellectual dis-
ability, coarse facial features, hypotonia, microcephaly,
hearing impairment, and joint contractures. The dis-
eases also display phenotypic abnormalities of the
skin, heart, urinary system, and skeleton, which are
less common features [3]. Reduced surface levels of
GPI-APs or abnormal GPI-AP structure are common
in IGD [23].
The first disease identified of the IGDs, hyperphosphata-
sia with mental retardation syndrome (HPMRS), is
associated with variants in both Synthesis-stage and
Transamidase+Remodeling-stage genes [24–29]. Specific-
ally, HPMRS is caused by mutations in one of the four
genes necessary for the biosynthesis of the GPI anchor in
the endoplasmic reticulum (PIGV, PIGO, PIGW, and
PIGY), or two genes necessary for the post-GPI attach-
ment to proteins (PGAP) type 2 (PGAP2) and type 3
(PGAP3) [24, 30]. Multiple congenital anomalies-
hypotonia-seizures (MCAHS) syndrome is a related dis-
order, although patients do not have hyperphosphatasia
(persistently elevated alkaline phosphatase). MCAHS1
[31–35] results from inherited PIGN mutations, a critical
gene within the GPI biosynthetic pathway [31, 32, 34].
There is considerable phenotypic variability in MCAHS1,
probably reflecting the fact that there is residual GPI asso-
ciated function [22, 33, 36]. Germline PIGA mutations
give rise to an X-linked MCAHS2 [14, 37, 38], and som-
atic mutations in bone marrow cells result in paroxysmal
nocturnal hemoglobinuria [39–41]. Finally, MCAHS3 syn-
drome results from the autosomal recessive inheritance of
mutations in PIGT [42–45]. Especially at the severe end of
the phenotypic spectrum of HPMRS, there is substantial
phenotypic overlap with MCAHS [46]. Additional IGDs
are not classified as either HPMRS or MCAHS have been
identified. An overview of all IGD described at the time of
this writing is provided in Tables 1 and 2.
A recent review of the phenotypes from 202 IGD
patients taken either from the literature or from in-
house clinical data chronicled the wide array of phe-
notypes observed with mutations in each of the GPI-
anchor biosynthesis pathway genes, including cogni-
tive impairment, seizures, and congenital malforma-
tions [3]. Here, we identified published clinical case
studies describing individuals with disease-causing
variants in any gene coding for an enzyme in the
GPI-anchoring biosynthesis pathway. We then com-
pared phenotypic differences in the Synthesis and
Transamidase+Remodeling stages of the GPI-
anchoring pathway utilizing the Human Phenotype
Ontology (HPO), a standardized vocabulary of pheno-
typic abnormalities [47]. We demonstrated a number
of statistically significant differences in the phenotypic
spectrum of diseases in the two groups, suggesting
that differential effects on the biochemical function of
the GPI pathway may result in different clinical mani-
festations. We reviewed the phenotypes of diseases
caused by defects in individual GPI-anchored proteins
and identified a number of candidate GPI-anchored
proteins that could cause individual component phe-
notypes that characterize the IGDs.
Results
In this work, we present a computational analysis to
address the question of whether there are differences
in the phenotypic spectrum of diseases associated
with genes in the Synthesis and Transamidase+Remo-
deling phases of GPI anchor biosynthesis (Fig. 1). We
first performed a comprehensive literature review of
all published case reports about individuals diagnosed
with diseases caused by variants in a GPI-anchor
pathway gene. We then extracted the patient informa-
tion, mutation(s) information, and all phenotypic data
about each patient using terms from the HPO [48–
50] (Tables 1 and 2). Clinical data from 58
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publications were included in this study, comprising a
total of 152 individual patients for whom detailed pheno-
typic descriptions were available, representing IGDs
associated with a total of 22 genes involved in the GPI-
biosynthesis pathway (Additional file 1: Table S1).
Synthesis vs. Transamidase+Remodeling phenotypes
We divided the GPI biosynthesis pathway into Synthesis
and Transamidase+Remodeling stages. Enzymes in the
Synthesis Group mediate assembly of the GPI precursor
backbone in the endoplasmic reticulum (ER) membrane.
Fig. 1 GPI biosynthesis pathway. Illustrated is the biosynthetic pathway of GPI-AP. In the Synthesis-stage, twenty genes are responsible for
synthesizing the GPI anchor (Synthesis Group, genes highlighted in red). The Transamidase+Remodelinglate-stage couples the protein to the GPI
anchor and mediates trafficking through the Golgi apparatus to the cell surface (Tranasmidase+Remodeling Group, genes highlighted in blue) [3–6].
Abbreviations: PI: phosphatidylinositol; EtNP: ethanolamine phosphate; GlcN: D-Glucosamine; GlcNAc: N-Acetyl-D-glucosamine; E.R.:endoplasmic
reticulum. Gene symbols: See Tables 1 and 2
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Enzymes in the Transamidase+Remodeling Group facili-
tate the coupling of the GPI to the C-terminus of a
newly synthesized protein within the lumen of the ER,
cleavage of a C-terminal GPI-addition signal peptide,
and enable lipid and carbohydrate side-chain modifica-
tions that regulate GPI-AP trafficking from the ER to
the plasma membrane [51] (Fig. 1, Tables 1 and 2).
We compared the phenotypic abnormalities in patients with
mutations in Synthesis and Transamidase+Remodeling Group
genes. Several skeletal phenotypes were significantly
more likely to occur in patients with mutations in the
Synthesis stage of the biosynthetic pathway (Synthesis
Group). The Synthesis Group had a greater occur-
rence (33% of patients) of Abnormal digit morphology
(HPO terms listed using italics). Other phenotypes
observed in the Synthesis Group patients were Absent
distal phalanges, Aplasia/Hypoplasia of fingers, Short digit,
Broad finger and Broad toe, Clubbing, Clinodactyly, and
Table 1 Genes in the GPI biosynthetic pathway anchoring process, Synthesis stage
Gene name (Entrez ID) # Patients
curated
Disease Association Inheritance
DPM1 (8813) 3 OMIM:608799 CDG, Type Ie [10] AR
DPM2 (8818) 3 OMIM:615042; CDG, Type Iu [11] AR
DPM3 (54344) 2 OMIM:612937 CDG, Type Io, Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 15 [12] AR
MPDU1 (9526) 1 OMIM:609180 CDG, Type If [13] AR
PIGA (5277) 21 OMIM:300868 Multiple Congenital Anomalies-hypotonia-seizures Syndrome 2 (MCAHS 2);
MIM:300818 Paroxysmal Nocturnal Hemoglobinuria 1 [14]
XLR
PIGB (9488) 0 n/a
PIGC (5279) 3 OMIM:617816 GPI Biosynthesis Defect 16 [15] AR
PIGF (5281) 0 n/a
PIGG (54872) 5 OMIM:616917 Mental Retardation, Autosomal Recessive 53 [16] AR
PIGH (5283) 1 OMIM: 618010 GPI Biosynthesis Defect 17 [17] AR
PIGL (9487) 8 OMIM:280000 Chime Syndrome [18–20] AR
PIGM (93183) 3 OMIM:610293 Glycosylphosphatidylinositol Deficiency [21] AR
PIGN (23556) 11 OMIM:614080 MCAHS 1 AR
PIGO (84720) 9 OMIM:614749 HPMRS 2 AR
PIGP (51227) 2 OMIM:617599 Epileptic Encephalopathy, Early Infantile, 55 (EIEE 55) [22] AR
PIGQ (9091) 1 Possible Association With Early Infantile Epileptic Encephalopathy (EIEE) [17, 18]
PIGV (55650) 13 OMIM:239300 HPMRS 1 AR
PIGW (284098) 3 OMIM:616025 GPI Biosynthesis Defect 11 AR
PIGX (54965) 0 n/a
PIGY (84992) 4 OMIM:616025 HPMRS 6 AR
AR Autosomal recessive, AD Autosomal dominant, XLR X-linked recessive. The Online Mendelian Inheritance in Man (OMIM) identifier for the disease is shown if
available. Abbreviations: GPI Glycosylphosphatidylinositol, HPMRS Hyperphosphatasia With Mental Retardation Syndrome, MCAHS Multiple congenital anomalies-
hypotonia-seizures, CDG Congenital Disorder Of Glycosylation, EIEE Early Infantile Epileptic Encephalopathy, PNH Paroxysmal Nocturnal Hemoglobinuria, ARMR
Autosomal recessive mental retardation. “n/a” is entered in the Disease Association column if no such association has been identified to date
Table 2 Genes in the GPI biosynthetic pathway anchoring process, Transamidase+Remodeling stage. Abbreviations as in Table 1
Gene name (Entrez ID) # Patients curated Disease Association Inheritance
GPAA1 (8733) 10 OMIM:617810 GPI biosynthesis defect 15 AR
MPPE1 (65258) 0 n/a
PGAP1 (80055) 7 OMIM: 615802 Mental retardation, autosomal recessive 42 AR
PGAP2 (27315) 10 OMIM: 614207 HPMRS 3 AR
PGAP3 (93210) 22 OMIM:615716 HPMRS 4 AR
PIGK (10026) 0 n/a
PIGS (94005) 0 OMIM:618143 GPI biosynthesis defect-18 AR
PIGT (51604) 10 OMIM:615399, Paroxysmal nocturnal hemoglobinuria 2, (PNH 2); MIM: 615398 MCAHS 3 AD/AR
PIGU (128869) 0 n/a
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other abnormalities (Table 3). Transamidase+Remodeling
Group patients (patients with mutations in the later stage
genes) had fewer incidences of Abnormal digit morphology
(6.7%, Table 3). For instance, Synthesis Group patients are
statistically more likely to have Short digit (24% of the pa-
tients), whereas only one individual (< 2%) was indicated
as having a Short digit in the Transamidase+Remodeling
Group (Table 3).
Moreover, Synthesis Group patients were significantly
more likely to have Abnormal muscle morphology, Ab-
normal tendon morphology, and/or Abnormal joint
morphology. This was mainly related to the term Flexion
contracture or descendants thereof (Fig. 2). Eighteen of
the ninety-three patients in the Synthesis group had a
flexion contracture of one or more joints (descendant of
Flexion contracture). A “contracture” is a shortening or
hardening of the muscle or tendon that leads to the loss
of motion of that joint and therefore is listed under the
muscle, tendon, and joint hierarchies of the HPO. In
addition to flexion contractures, a handful of other types
of phenotypes add significance to these parent classes.
One Synthesis Group patient [12] displayed Abnormality
of the Achilles tendon which is a child of Abnormal ten-
don morphology. As for Abnormality of joint morphology,
a single patient had Axillary pterygia, which is the pres-
ence of a cutaneous membrane in the armpit [31].
Additionally, several Synthesis Group patients and a sin-
gle Transamidase+Remodeling Group patient had Joint
hypermobility (Tables 1 and 2). Besides contractures,
several other observed phenotypes contributed to the
Abnormal muscle morphology phenotype being signifi-
cantly increased in the Synthesis Group. Such pheno-
types include Muscle dystrophy, Camptodactyly,
Generalized amyotrophy, Macroglossia, Myopathy,
Rimmed vacuoles, Muscle fiber splitting, Skeletal muscle
atrophy, Abnormal muscle, and fiber dystrophin expres-
sion. Two Transamidase+Remodeling Group patients
have noted Abnormal muscle morphology, but this group
differs in the types of phenotypes reported (Skeletal
muscle atrophy and Increased muscle lipid content).
Transamidase+Remodeling Group patients, overall,
displayed more diverse phenotypic abnormalities that se-
lectively affected this population as opposed to the
Synthesis Group (Tables 3 and 4). The most common al-
terations were in bone and facial development and
neurodevelopmental disabilities. The frequency of Ab-
normality of bone density is significantly higher in Trans-
amidase+Remodeling Group patients as compared to
Synthesis Group patients. Osteopenia, a reduction in
bone mineral density below normal but not as severe as
Osteoporosis, occurred in 22% of the Transamidase+Re-
modeling Group patients, while only 2% of the patients
in the Synthesis Group were reported to have Osteope-
nia. Osteopenia contributes almost entirely to the signifi-
cance identified in Reduced bone mineral density (parent
term), Abnormality of bone mineral density (grandparent
term), Abnormal bone ossification (great-grandparent
term), and Abnormal bone structure (great-great-grand-
parent term) in the Transamidase+Remodeling Group
patients. The only additional Abnormal bone structure
phenotypes observed were a Thin bony cortex observed
in a single patient in the Synthesis Group [52], and two
patients were observed to have Reduced bone mineral
density and Osteoporosis in one patient in the Transami-
dase+Remodeling Group [42] (Table 4).
Similarly, patients in the Transamidase+Remodeling
Group, predominantly patients with PGAP3 mutations,
are significantly more likely to having Macrotia. The
Transamidase+Remodeling Group patients were classi-
fied as having Macrotia (large ears greater than 2x the
standard deviation) 25% of the time, while the incidence
was only 2% for the Synthesis Group patients. The vast
majority of these Transamidase+Remodeling Group pa-
tients were described as specifically having Large fleshy
ears, a child of Macrotia (Table 4).
Other facial developmental abnormalities found in
Transamidase+Remodeling Group patients were
Abnormal hard palate morphology and its child term,
Cleft palate. Both phenotypes occurred with significantly
higher frequency in the Transamidase+Remodeling
Group as compared to the Synthesis Group (29% vs. 6%
of patients) (Table 4, Fig. 2). Cleft palate was the pre-
dominant phenotype identified 16 Transamidase+Remo-
deling Group patients (vs. 6 patients in the Synthesis
Group), which resulted in both Abnormal hard palate
morphology and Cleft palate reaching significance.
Table 3 Significantly Overrepresented Synthesis-Group Phenotypes
HPO ID Term Name Synthesis Group
(patients with
phenotype/total)
Synthesis
Group (%)
Transamidase + Remodeling
Group (patients with
phenotype/total)
Transamidase +
Remodeling Group (%)
Corrected p-value
HP:0011297 Abnormality of digit 31/93 33.3 4/59 6.8 0.03185
HP:0011805 Abnormal muscle morphology 25/93 26.9 2/59 3.4 0.04678
HP:0011927 Short digit 22/93 23.7 1/59 1.7 0.04883
HP:0001367 Abnormal joint morphology 22/93 23.7 1/59 1.7 0.04883
HP:0100261 Abnormal tendon morphology 19/93 20.4 0/59 0.0 0.04346
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Additionally, two patients in the Transamidase+Remo-
deling Group were described as having Median cleft lip
and palate, great-grandchild of Cleft palate, which also
contributed to the significance of these two phenotypes
(Table 4, Fig. 2). Because the term Cleft palate has mul-
tiple parents in the HPO, Oral cleft was also identified
as selectively enriched in Transamidase+Remodeling
Group patients. Besides the phenotypes already men-
tioned, the significance of the term Oral cleft stemmed
from Cleft upper lip and Cleft lip (Table 4, Fig. 2).
Numerous patients in both groups have Abnormality
of the nose, but patients in the Transamidase+Remodel-
ing Group were significantly more likely to have
alterations in their nose (Synthesis Group = 28% vs.
Transamidase+Remodeling Group = 61%). Both groups
have Abnormalities of the nose, such as Broad nasal tip
and Wide nasal bridge being the most common in each
group. While many of the nose abnormalities are present
in both groups, Prominent nose was only found in the
Transamidase+Remodeling Group (15%). Prominent
nose appears to be strongly associated with mutations in
PGAP3 and was only reported in those patients. One pa-
tient in the Synthesis Group had a Prominent nasal
bridge (Table 4).
There are numerous mental and cognitive phenotypes
affecting both groups, however, the Remodeling Group
appears to have been impacted more often. While both
groups have a large percentage of patients with Neurode-
velopmental abnormality, 98% of the Transamidase+Re-
modeling Group were noted with Neurodevelopmental
abnormality, as opposed to 73% of the Synthesis Group.
More specifically, the Transamidase+Remodeling
Group had an increased incidence of Neurodevelop-
mental delay, Intellectual disability, and Behavioral
abnormality (92, 66, and 42%, respectively) while the
Synthesis Group had a significantly smaller population
with these abnormalities (61, 16, and 15%, respect-
ively) (Table 4).
Fig. 2 Example of HPO hierarchy. The hierarchy in the HPO for cleft palate and neighboring phenotypes
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The division we chose between Synthesis and Transa-
midase+Remodeling Groups is but one of many possible
ways of dividing the GPI pathway, and we reasoned that
other partitionings might display other phenotypic dif-
ferences. In order to explore this, we defined a group
consisting of the GPI synthesis genes as well as the
transamidase complex genes (Synthesis+Transamidase
Group) and compared it with the genes responsible for
fatty-acid remodeling (Remodeling Group). The Remod-
eling group consists of the genes PGAP1, PGAP3,
PGAP2, and PGAP5 (a subset of the original Transami-
dase+Remodeling Group). The Synthesis+Transamidase
Group showed enrichment of Urinary tract anomalies.
The Remodeling group showed enrichment for some of
the same terms as in the Transamidase+Remodeling
Group, including Behavioral abnormality, Neurodevelop-
mental delay, Abnormality of the hard palate, Oral cleft,
and Cleft palate. Additionally, the Remodelling group
had Decreased head circumference, Altered eye location,
Ear and Eyelid morphology abnormalities, Wide nasal
bridge, Upper lip abnormalities, and Elevated alkaline
phosphatase (Additional file 1: Table S3).
Candidate causal genes for component phenotypes of the
IGDs
Mutations in genes that encode enzymes of the GPI bio-
synthesis pathway result in mistargeting of GPI-APs
[53], but the abnormal distribution of GPI-APs in the
IGDs has not been characterized in detail. Our hypoth-
esis is that mis-anchoring and, therefore, mistargeting of
individual GPI-APs leads to dysfunction of the targeted
proteins which in turn leads to some or all of the pheno-
typic abnormalities observed in the IGDs. A better
understanding of the mistargeting of GPI-APs could,
therefore, clarify the molecular pathogenesis of the IGDs
and shed light on genotype-phenotype correlations.
Over 142 human proteins have been identified in Uni-
Prot as being GPI-anchored (Additional file 1: Table S2).
Of these, 23 (or 16%) of these genes encoding for
GPI-APs have been associated with at least one
Mendelian disease (a total of 34 Mendelian diseases
were identified), and therefore, numerous phenotypes
that define these diseases. We did not observe a sig-
nificant enrichment of Gene Ontology terms for the
genes, nor an enrichment of Mammalian Phenotype
Ontology terms (including embryonic lethality) among
the orthologs of these genes (data not shown). Thirty-
four phenotypes in patients with mutations in GPI-
anchored genes overlap with the phenotypes of CDG
patients (Table 1 and 2). The fact that GPI-
biosynthesis gene mutation and GPI-anchored gene
mutations may cause overlapping but not identical
phenotypes is expected since mutations in the GPI-
biosynthesis pathway would likely alter the activity
and function of a number of GPI-anchored proteins,
and therefore, multiple signaling pathways.
Table 4 Significantly Overrepresented Transamidase+Remodeling-Group Phenotypes
HPO ID Term Name Synthesis Group
(patients with
phenotype/total)
Synthesis
Group (%)
Transamidase+Remodeling
Group (patients with
phenotype/total)
Transamidase+
Remodeling
Group (%)
Corrected p-value
HP:0002360 Sleep disturbance 0/93 0.00 13/59 22.03 0.00047
HP:0012759 Neurodevelopmental
abnormality
68/93 73.12 58/59 98.31 0.01235
HP:0000708 Behavioral abnormality 14/93 15.05 25/59 42.37 0.03610
HP:0012758 Neurodevelopmental delay 57/93 61.29 54/59 91.53 0.00898
HP:0001249 Intellectual disability 15/93 16.13 39/59 66.10 0.00000
HP:0003330 Abnormal bone structure 3/93 3.23 15/59 25.42 0.00773
HP:0011849 Abnormal bone ossification 2/93 2.15 15/59 25.42 0.00193
HP:0004348 Abnormality of bone
mineral density
2/93 2.15 15/59 25.42 0.00193
HP:0004349 Reduced bone mineral
density
2/93 2.15 15/59 25.42 0.00193
HP:0000938 Osteopenia 2/93 2.15 13/59 22.03 0.01305
HP:0000400 Macrotia 2/93 2.15 15/59 25.42 0.00193
HP:0002265 Large fleshy ears 1/93 1.08 14/59 23.73 0.00106
HP:0000366 Abnormality of the nose 26/93 27.96 36/59 61.02 0.01119
HP:0100737 Abnormal hard palate morphology 6/93 6.45 17/59 28.81 0.03743
HP:0000202 Oral cleft 6/93 6.45 18/59 30.51 0.01556
HP:0000175 Cleft palate 6/93 6.45 17/59 28.81 0.03743
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To further delve into the pathways affected by GPI-
biosynthesis gene mutations, we investigated the pheno-
types that were observed to be more frequent in the Syn-
thesis or Transamidase+Remodeling Groups. In the
Synthesis Group, genes associated with the 5 characteristic
phenotypes (Table 3) were compared. A total of 102 genes
were associated with Mendelian diseases that share each of
the five phenotypic features (Additional file 1: Figure S1).
When comparing the genes associated with the
Transamidase+Remodeling Group, two genes were as-
sociated with 15 of the 16 Transamidase+Remodeling
Group enriched phenotypes: fibroblast growth factor
receptor tyrosine kinase (FGFR2), and a downstream
signaling partner, B-Raf (BRAF) (Additional file 1:
Figure S2). FGFR2 and B-Raf are associated with all
the Transamidase+Remodeling Group phenotypes
except Large fleshy ears. Notably, these genes are
associated with the parent term of Large fleshy ears,
Macrotia. The exclusion of Large fleshy ears may be
due to the fact that patients present with large ears
but not Large fleshy ears, or it could be due to the
specificity in which physicians are presenting patient
data or the detail recorded by curators and re-
searchers. Mutations in FGFR2 are associated with
over ten distinct diseases including Pfeiffer syndrome
and Crouzon syndrome [16, 54]. Mutations in BRAF
are associated with seven diseases including Noonan
syndrome type 7 and Cardiofaciocutaneous syndrome.
Although neither FGFR2, a membrane-spanning pro-
tein, nor B-Raf has been identified as GPI-APs, FGFR2 has
been shown to associate with lipid rafts in oligodendro-
cytes [55] and osteoblasts [56] and B-Raf translocation oc-
curs more rapidly in the presence of lipid rafts [57]. GPI-
APs are associated with lipid rafts [1, 7] suggesting that
this may be a key altered pathway for Transamidase+Re-
modeling-Group-specific mutations (Fig. 3). Several other
signaling partners within the FGFR2 pathway are also as-
sociated with lipid rafts, including ligand FGF2 [55, 58],
and FRS2 [55]. There may be several targets or interac-
tions with GPI-APs and FGFR2 signaling pathways.
Interestingly, two target proteins, GPC3 and GPC6 are
associated with 25 of GPI-AP associated phenotypic ab-
normalities (Table 5). Both proteins are members of the
glypican family of heparan sulfate proteoglycans that are
bound to the cytoplasmic surface of the plasma mem-
brane through a covalent GPI linkage. GPC3 can act as
an FGFR1 and FGFR2 coreceptor required for the recep-
tion and subsequent relay of the FGF9 signals respon-
sible for the control of coronary vascular development
[59], suggesting a possible link.
Discussion
The 29 GPI-biosynthesis enzymes are critical for build-
ing the GPI backbone, adding the GPI anchor to
proteins, and targeting them to subcellular compart-
ments. The first ~ 20 genes in the pathway are dedicated
to building the GPI anchor, while the last ~ 9 genes an-
chor the proteins to the GPI backbone, and further
modify the backbone, thereby regulating targeting of the
anchored protein (Table 1). We hypothesized that the
clinical features of diseases associated with either the
Synthesis or the Transamidase+Remodeling stage of the
GPI-biosynthesis pathway may be significantly distinct
in each group. Although naively one might think that a
mutation of any component of the GPI biosynthesis
pathway would have identical phenotypic consequences,
it is likely that defects in various components of the
pathway affect the biochemistry and functions of GPI-
anchored proteins in different ways. Our analysis
showed 5 phenotypic abnormalities that were signifi-
cantly more common with mutations in Synthesis
pathway genes and 16 abnormalities that were more
common with mutations in Transamidase+Remodeling
pathway genes.
While our computational analysis is not able to iden-
tify the biochemical mechanisms underlying these differ-
ences, we can speculate about the range of factors that
might be involved. IGDs do not lead to a uniform
reduction of GPI-APs on all cells. For example, some pa-
tients with mental retardation, autosomal recessive 53
(MRT53) resulting from variants of PIGG have normal
GPI expression on granulocytes while fibroblasts show a
reduced global level of GPI anchors and of specific GPI-
linked markers [60]. Therefore, one potential factor re-
lated to different phenotypic spectrums of the IGDs
might be related to the distribution and degree of reduc-
tion of GPI-APs in different tissues [61].
The biochemical consequences of individual GPIs may
be specific to particular tissues or developmental stages
and would affect the target proteins, the GPI-APs, differ-
entially, leading to different phenotypic consequences.
The Synthesis Group displayed an enrichment of terms
related to Flexion contracture, Abnormal digit, and Short
digit, while the Synthesis Group showed an overrepre-
sentation of Neurodevelopmental abnormalities, Bone
density abnormalities, and additional facial developmen-
tal anomalies (Tables 3 and 4), which we speculate sug-
gests a differential effect of mutations in Synthesis and
Transamidase+Remodeling genes on the corresponding
tissues.
The analyses of the Synthesis vs. Transamidase+Remo-
deling Groups, as well as the Synthesis+Transamidase
vs. Remodelling groups, clearly demonstrate that the
phenotypic abnormalities observed with mutations of
genes involved in the GPI-biosynthesis pathway are not
consistent across all of the genes. We limited our ana-
lysis to two comparisons and showed statistically signifi-
cant differences in each case. As larger numbers of case
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reports become available, it may be possible to identify
significant differences on a finer scale, involving smaller
groups of genes, individual genes, or even specific vari-
ants. Understanding these differences may be helpful for
precision management or even treatment of the GPI dis-
eases in the future.
Methods
Patient selection
An extensive literature search was conducted using Clin-
var [62], Pubmed, OMIM [63], and references for each
GPI-anchoring gene to identify case studies. Searches
were initiated using the terms “GPI”, “glycosylphosphati-
dylinositol”, and “mutation”, allowing citations in each
publication to be looked up. Variants associated with
each disease-related gene in the GPI pathway were ex-
amined in ClinVar to identify relevant case reports con-
taining phenotypic descriptions. All case studies of
individuals with pathogenic mutations in the GPI-
anchoring synthesis pathway were included as long as
they met the following criteria: an identifiable mutation
was presented, phenotypic information about the patient
was included, and the patient was not already included
in another paper (See Tables 1, 2, Additional file 1:
Table S4). Patient identifiers, phenotypes, and genetic
variants were recorded.
Biocuration
Biocuration was performed with an in-house and freely
available Java desktop tool for the curation of case re-
ports called HpoCaseAnnotator (https://github.com/
monarch-initiative/HpoCaseAnnotator). The tool was
used to enter and track PMID, variant information, pa-
tient ID, and phenotype(s) associated with each patient.
HpoCaseAnnotator offers a concept recognition tool
and other convenient functions to streamline HPO-
based phenotype annotation. HpoCaseAnnotator calls
VariantValidator [64] to check the HGVS syntax and
chromosomal locations of variants.
Analysis of the distribution of phenotypes in the selected
groups
The biocurated case reports were used to analyze the dis-
tribution of phenotypic features within selected groups.
Patients were classified into either Synthesis and Transa-
midase+Remodeling Groups or Synthesis+Transamidase
Fig. 3 Schematic representation of FGFR2 signaling through the Ras/Raf/MAPK pathway. FGFR2 and B-Raf were found 2 associated with 15 of 16
phenotypes over-represented in the Transamidase+Remodeling Group and are in signaling cascades associated with lipid rafts which contain
GPI-anchored proteins. *Numerous FGFs activate the FGFR2. Only FGF2 is known to be associated with lipid rafts (purple) [55–58]
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and Remodeling Groups according to the gene mutation
identified (Table 1, Additional file 1: Table S1, Additional
file 1: Table S4). For each HPO term appearing in any pro-
band record, the software counts the number of patients
in each group annotated with that term. These counts are
propagated upward in the HPO hierarchy so that a patient
annotated with term T is included in the count for any
term that subsumes T (i.e., for ancestors of T in the ontol-
ogy). For instance, if a patient is annotated to Flexion con-
tracture of the 2nd finger (HP:0009537), then implicitly
the patient is also annotated to Flexion contracture of
finger (HP:0012785) and Abnormal 2nd finger morphology
(HP:0004100), as well as all the ancestor terms on the path
to the root of the ontology. Using a χ2 test with one degree
of freedom, the incidence of each phenotype term was
compared between the two groups. Comparisons with in-
sufficient data (expected value below 5 in any cell of the
2 × 2 contingency table) were omitted. A Bonferroni cor-
rection for multiple comparisons was applied to achieve α
≤ 0.05. The analysis was implemented as a Java application
(code available at https://github.com/monarch-initiative/
phenoCompare, release v1.0.0).
Table 5 A selected list of GPI-anchored genes that when mutated give rise to overlapping phenotypes with CDG patients
HPO Term GPI-anchored genes
APLI ALPL ALPP ALPPL2 CNTN1 FOLR1 GPC6 GPC3 CD59 CNTN2 GPIHBP1 CD55
Hyperphosphatasia x x x x
High palate x
Hypertelorism x x
Muscular hypotonia x x x
Generalized hypotonia x x
Polyhydramnios x
Feeding difficulties x
Camptodactyly x
Intellectual disability x
Seizures x x
Malar flattening x
Epicanthus x x
Micrognathia x
Depressed nasal bridge x x
Wide nasal bridge x x
Short neck x
Atrial septal defect x
Frontal bossing x
Short nose x x
Tremor x
Cleft palate x
Coarse facial features x
Hepatomegaly x x x
Macrocephaly x
Patent ductus arteriosus x
Short distal phalanx of finger x
Small nail x
Splenomegaly x x
Anteverted nares x
Wide mouth x
Splenomegaly x
Failure to thrive x
Growth delay x
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